biotech / news / / MarketScreener
Pfizer says its blood-cancer treatment met the main goal of an ongoing late-stage study.
Pfizer's Elrexfio met the main goal in a late-stage study for multiple myeloma.
KEY POINTS
- The drug significantly extended progression-free survival compared to a standard drug combination.
- Elrexfio's safety profile in the trial was consistent with previous studies.
- Pfizer aims to expand Elrexfio's approval from heavily pretreated to earlier-line patients.
- Overall survival data from the trial is not yet mature and continues to be collected.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →